Clindamycin Injection (Iv/Im) Suppliers & Bulk Manufacturers
Available Forms: Injection (IV/IM)
Available Strengths: 300 mg/2 mL, 600 mg/4 mL
Reference Brands: Cleocin, Clindamycin, Dalacin C(US); Dalacin C, Clindamycine(EU)
Category:
Antibiotics
Clindamycin IV and IM inhibit bacterial protein synthesis by binding to the 50S ribosomal subunit, leading to bacterial cell death. It effectively treats severe skin, respiratory, and intra-abdominal infections. Benefits include rapid, reliable action against anaerobic bacteria, good tissue penetration, and clinical utility in hospital settings.
Clindamycin Injection (IV/IM) is available in Injection (IV/IM)
and strengths such as 300 mg/2 mL, 600 mg/4 mL.
Sourced from GMP-certified and ISO-compliant manufacturers, this API meets
global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical
formulation and commercial manufacturing, Clindamycin Injection (IV/IM) is supplied in
bulk quantities with complete regulatory support including DMF, COA, and MSDS.
|
Technical Specifications & Supply Details
|
| Lead Time |
7 to 60 days (depending on batch size & schedule) |
| MOQ |
As per manufacturer’s batch size |
| COA |
Available with every batch |
| Regulatory Dossier / DMF |
Available upon request |
| Export Documentation |
FSC, COA, Manufacturing License, Product Permission |
| Standards |
IP, BP, USP |
| Certifications |
WHO-GMP, EU-GMP, USFDA (as applicable) |
Clindamycin Injection (IV/IM) can be exported to over 30 countries across Asia, Africa, Europe,
and Latin America. Flexible packaging, competitive pricing, and a verified supplier
network make Pharmatradz a trusted sourcing partner for pharmaceutical companies
and contract manufacturers worldwide.
Product Description:
Clindamycin IV/IM is approved in the EU and US for severe bacterial infections, including skin, respiratory, and intra-abdominal infections. In the EU, brands like Cleocin are regulated by EMA, supported by dossiers demonstrating safety, efficacy, and manufacturing quality. In the US, FDA approval relies on extensive clinical data; generic formulations are widely available. Both regions require detailed dossiers, including clinical trial results, manufacturing standards, and pharmacovigilance plans for approval and ongoing safety monitoring. For expert regulatory support, dossier preparation, and compliance, visit PharmaTradz. We facilitate seamless market access for clindamycin IV/IM, ensuring adherence to European and US standards for safe, effective antimicrobial therapy.
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Back to Listing